{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:02Z","timestamp":1791472082424,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Teclistamab, a B-cell maturation antigen (BCMA)\u2009\u00d7\u2009CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively assessed efficacy and tolerability in 123 patients treated at 18 different German centers to determine whether outcome is comparable in the real-world setting. Most patients had triple-class (93%) or penta-drug (60%) refractory disease, 37% of patients had received BCMA-directed pretreatment including idecabtagene vicleucel (ide-cel) CAR-T cell therapy (21\/123, 17.1%). With a follow-up of 5.5 months, we observed an overall response rate (ORR) of 59.3% and a median progression-free survival (PFS) of 8.7 months. In subgroup analyses, we found significantly lower ORR and median PFS in patients with extramedullary disease (37%\/2.1 months), and\/or an ISS of 3 (37%\/1.3 months), and ide-cel pretreated patients (33%\/1.8 months). Nonetheless, the duration of response in ide-cel pretreated patients was comparable to that of anti-BCMA naive patients. Infections and grade \u22653 cytopenias were the most frequent adverse events. In summary, we found that teclistamab exhibited a comparable efficacy and safety profile in the real-world setting as in the pivotal trial.<\/jats:p>","DOI":"10.1038\/s41375-024-02154-5","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T10:02:09Z","timestamp":1705744929000},"page":"365-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Real-world analysis of teclistamab in 123 RRMM patients from Germany"],"prefix":"10.1038","volume":"38","author":[{"given":"C.","family":"Riedhammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bewarder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carpinteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Faltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Frenking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goldman-Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. M.","family":"Kortuem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-0506","authenticated-orcid":false,"given":"J.","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9374-300X","authenticated-orcid":false,"given":"R.","family":"Mecklenbrauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"M.","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"M. S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"R.","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"L.","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"key":"2154_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38:775\u201383.","journal-title":"J Clin Oncol"},{"key":"2154_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2154_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2154_CR4","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"2154_CR5","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/blood.2019004176","volume":"136","author":"L Rasche","year":"2020","unstructured":"Rasche L, Hudecek M, Einsele H. What is the future of immunotherapy in multiple myeloma? Blood. 2020;136:2491\u20137.","journal-title":"Blood"},{"key":"2154_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"2154_CR7","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4:4538\u201349.","journal-title":"Blood Adv"},{"key":"2154_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"2154_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen\u2009\u00d7\u2009CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374.","journal-title":"Lancet"},{"key":"2154_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346.","journal-title":"Lancet Oncol"},{"key":"2154_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"2154_CR12","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"2154_CR13","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol. 2022;40:2246\u201356.","journal-title":"J Clin Oncol"},{"key":"2154_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98:1540\u20139.","journal-title":"Am J Hematol"},{"key":"2154_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"EW Meermeier","year":"2021","unstructured":"Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2:354\u201369.","journal-title":"Blood Cancer Discov"},{"key":"2154_CR16","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390.","journal-title":"Leukemia"},{"key":"2154_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","volume":"35","author":"AH Wei","year":"2021","unstructured":"Wei AH, Ribera J-M, Larson RA, Ritchie D, Ghobadi A, Chen Y, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021;35:2220\u201331.","journal-title":"Leukemia"},{"key":"2154_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol"},{"key":"2154_CR19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136.","journal-title":"Nat Med"},{"key":"2154_CR20","doi-asserted-by":"publisher","unstructured":"Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, et al. Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Invest. 2023;133, https:\/\/doi.org\/10.1172\/JCI167629.","DOI":"10.1172\/JCI167629"},{"key":"2154_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2154_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-134369","volume":"136","author":"J Rytlewski","year":"2020","unstructured":"Rytlewski J, Madduri D, Fuller J, Campbell TB, Mashadi-Hossein A, Thompson EG, et al. Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma. Blood. 2020;136:7\u20138.","journal-title":"Blood"},{"key":"2154_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CJI.0000000000000267","volume":"42","author":"J Duell","year":"2019","unstructured":"Duell J, Lukic DS, Karg M, Reusch U, Koch J, Zhukovsky EA, et al. Functionally defective T cells after chemotherapy of B-cell malignancies can be activated by the tetravalent bispecific CD19\/CD3 antibody AFM11. J Immunother. 2019;42:180.","journal-title":"J Immunother"},{"key":"2154_CR24","doi-asserted-by":"publisher","first-page":"10144","DOI":"10.1182\/blood-2022-160451","volume":"140","author":"N Callander","year":"2022","unstructured":"Callander N, Silbermann R, Kaufman JL, Godby KN, Laubach JP, Schmidt TM, et al. Analysis of transplant-eligible patients (pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the Griffin and master studies. Blood. 2022;140:10144\u20137.","journal-title":"Blood"},{"key":"2154_CR25","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","volume":"40","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. J Clin Oncol. 2022;40:8013\u20138013.","journal-title":"J Clin Oncol"},{"key":"2154_CR26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"2154_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616\u20139.","journal-title":"Nat Med"},{"key":"2154_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai Y-T, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"2154_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"N Leblay","year":"2020","unstructured":"Leblay N, Maity R, Barakat E, McCulloch S, Duggan P, Jimenez-Zepeda V, et al. Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood. 2020;136:11\u201312.","journal-title":"Blood"},{"key":"2154_CR30","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2022-168903","volume":"140","author":"MK Samur","year":"2022","unstructured":"Samur MK, Martin N, Thompson E, Fulciniti M, Aktas-Samur A, Kaiser S, et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood. 2022;140:2106\u20137.","journal-title":"Blood"},{"key":"2154_CR31","doi-asserted-by":"crossref","unstructured":"Rasche L, Vago L, Mutis T. Tumour escape from CAR-T cells. In: Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H editors. The EBMT\/EHA CAR-T Cell Handbook, Cham: Springer; 2022. 15\u201322.","DOI":"10.1007\/978-3-030-94353-0_4"},{"key":"2154_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2022-157767","volume":"140","author":"DE Lowther","year":"2022","unstructured":"Lowther DE, Houseman EA, Han G, Kleanthous E, Knoblock D, Zhou X, et al. No evidence of BCMA expression loss or systemic immune impairment after treatment with the BCMA-targeted antibody-drug conjugate (ADC) belantamab mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 trials of patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2022;140:611\u20133.","journal-title":"Blood"},{"key":"2154_CR33","doi-asserted-by":"crossref","unstructured":"MM-192 preliminary recommendations for prevention and management of infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab based on experience from the MajesTEC-1 study. Clin Lymphoma Myeloma Leuk. 2023;23:S480\u2013S481.","DOI":"10.1016\/S2152-2650(23)01416-7"},{"key":"2154_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02154-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02154-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02154-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:07:18Z","timestamp":1707131238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02154-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2154"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02154-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BB has received honoraria from Janssen and GSK. MB has received speaker honoraria from AstraZeneca and Incyte and travel grants from Janssen. AC received consulting and\/or lecture fees from Amgen, Janssen, Pfizer and Takeda and travel and congress participation grants from Janssen. HE has consulted for BMS\/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK and Novartis, he has received research funding by BMS\/Celgene, Janssen, Amgen, GSK, Sanofi, honoraria from BMS\/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis and travel support from BMS\/Celgene, Janssen, Amgen, Takeda, Novartis, Sanofi. AN has consulted for Celgene, Roche, Takeda, Alexion, Janssen, BMS, Sanofi, Amgen and GSK. He received honoraria from Celgene, Roche, Takeda, Alexion, Janssen, BMS, Sanofi, Amgen, GSK and Jazz and research support from BMS, Janssen and Celgene. KMK received honoraria from from Abbvie, BMS, GSK, Janssen, Pfizer and Takeda. MM has received honoraria from Amgen, Takeda, BMS, Janssen, Stemline and Roche. MSR received honoraria and consulted for Janssen, BMS, Sanofi, Amgen, AbbVie and GSK. RT received honoraria and research funding from Janssen. RW consulted for Amgen, BMS\/Celgene, Janssen, Novartis, Kite\/Gilead, Pfizer, Sanofi and Takeda, he received research funding from Janssen and Sanofi, and travel support from Janssen, Kite\/Gilead, Pfizer and BMS. LR consulted for Janssen, Amgen, GSK, Pfizer, BMS, Sanofi, and received honoraria from Janssen, GSK, Pfizer, BMS, Sanofi and received research funding from Skyline Dx and BMS. CR, FBa, FBr, JFa, JFr, DG, SG-M, MH\u00e4, MHo, JK, MK, TL, CM, RM, AM declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}